Monoamine oxidase is a mitochondrial outermembrane flavoenzyme that is a target for antidepressant and neuroprotective drugs.

Monoamine Oxidase inhibitors (MAOIs) are used to treat mental disorders including depression and Parkinson′s.

This product is suitable as a negative control for MAO-A and MAO-B.

Monoamine Oxidase (MAO) is an integral flavoprotein of the outer mitochondrial membrane. MAOs are responsible for catalyzing the oxidative deamination of a wide variety of xenobiotic and endobiotic primary, secondary, and tertiary amines. The primary endogenous function of MAOs involves the inactivation of monoamine neurotransmitters, such as serotonin and dopamine. MAOs exist in two isoforms, MAO-A and MAO-B, which share approximately 70% sequence identity on the amino acid level.1 Both isoforms are nearly ubiquitous in mammals, but show particularly high enzymatic activity in the central nervous system and liver.